ASME.MVC.Models.DynamicPage.ContentDetailViewModel ContentDetailViewModel
ASME Hosts Virtual Briefing on Regenerative Medicine

ASME Hosts Virtual Briefing on Regenerative Medicine

On January 25, ASME Government Relations hosted a virtual briefing for industry leaders and federal policymakers to address the opportunities and challenges in regenerative medicine. Five leaders representing various sectors of the biomanufacturing and regenerative medicine community provided a snapshot of current advancements in the field, as well as the scientific, regulatory, and business challenges impacting these advances.

The field of regenerative medicine—the process of regenerating human cells and tissue in humans to restore damaged or diseased organs or bodily functions—is advancing exponentially. As the United States seeks to maintain its competitive status as a leading biomedical innovator, the engineering community is playing a vital role.
The program was moderated by Joshua Hunsberger, Ph.D., Chief Technology Officer of RegenMed Development Organization (ReMDO) & Executive Director, Regenerative Medicine Manufacturing Society. He was joined by panelists Mark Wolff, M.S., Ph.D., Chief Health Analytics Strategist, Global IoT Division, SAS Institute & Visiting Fellow, Institute for Data Science and Computing, University of Miami; Randy Yerden, Chief Executive Officer, BioSpherix LTD; Steven Bauer, Chief Regulatory Science Affairs Program Officer, Wake Forest Institute for Regenerative Medicine (WFIRM); and Israr Kabir, Senior Manager of Emerging Technologies for ASME.
“At first glance, regenerative medicine seems to be more about biology and medicine,” explained Kabir during his segment of the briefing. “But mechanical engineers have an understanding of the thermal transfer process and a role in setting those standards for the industry.” He pointed to the formation of ASME’s Standards for Regenerative Medicine and Committee on Thermal Medicine as examples of ASME’s leadership on the issues.
“A multidisciplinary approach will accelerate the pace at which we advance biomanufacturing, and address challenges [in regenerative medicine],” noted Bauer, Chief Regulatory Science Affairs Program Officer at the Wake Forest Institute for Regenerative Medicine. ASME also is advocating in Washington for policies that support these advancements and remove the barriers.
To learn about future engineering-centered briefings, visit here

You are now leaving